Press Releases

Leal Therapeutics Announces $45 Million Financing to Progress Novel Therapies for Patients with Major Neurodegenerative and Neuropsychiatric Disorders

October 30, 2024

In the News

Endpoints News
Exclusive: Top neuroscientist Asa Abeliovich targets ALS, schizophrenia with new startup Leal after $1B Lilly buyout

February 7, 2024

Endpoints News
Scoop: Star neuroscientist Asa Abeliovich and OrbiMed are teaming on yet another biotech

February 14, 2022